Updated: March 29, 2026

Semaspace

Name: Semaspace
Brand: Semaspace
Rating: 0

Learn about Semaspace, an online vendor cited by the FDA for selling unapproved semaglutide products without a prescription-based telehealth model.

Patient's Rating

0 Reviews

Provider Profile Name: Semaspace
Website: semaspace.com
Provider Type: Unapproved Drug Vendor
FDA Warning Letter: October 2, 2023

Operating Details

E-commerce vendor selling injectable semaglutide products labeled “Generic semaglutide 2mg” and “Generic semaglutide 5mg”
No FDA-approved drug applications are in effect for the semaglutide products offered by semaspace.com — the products are unapproved new drugs and misbranded under the Federal Food, Drug, and Cosmetic Act
No prescription required for purchase at the time of FDA enforcement action
Not a licensed telehealth platform — no physician consultation, no clinical oversight
No 503A or 503B pharmacy relationship disclosed

About the Company

The FDA issued a warning letter to semaspace.com on October 2, 2023, citing the website’s offer of semaglutide drug products marketed as “Semaglutide 2mg” and “Generic semaglutide 2mg vial” and “Semaglutide 5mg” and “Generic semaglutide 5mg vial” unapproved and misbranded drugs introduced into interstate commerce in violation of the Federal Food, Drug and Cosmetic Act.

The FDA’s characterization of the regulatory violations is specific: while there are FDA-approved semaglutide products on the US market, there were no approved drug applications in effect for the “Semaglutide 2mg” or “Semaglutide 5mg” products offered by semaspace.com. Because the drugs are prescription products intended for conditions not amenable to self-diagnosis and treatment by a layperson, adequate directions for use cannot be written for them, making the labeling misbranded under section 502(f)(1) of the FD&C Act.

The marketing language on Semaspace’s website at the time of the warning letter described weight loss indications in clinical terms stating “Semaglutide helps balance out hormones like insulin, significantly reduces blood sugar, and therefore suppresses your appetite and reduces food cravings” and listing “Excessive body weight,” “Obesity,” and “Excessive hunger and cravings” as conditions for which the product was needed. This combination of unapproved drug status, prescription-required active ingredient, and therapeutic claims directed at weight loss patients is precisely the regulatory profile that triggers FDA enforcement.

The FDA’s warning letter notes that unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight and that drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. The injectable nature of the products heightens the public health concern, as improperly manufactured injectables carry additional risks of contamination and infection.

GLP-1 Weight Loss

Lose pounds of fat every week
Money Back Guarantee
No membership or hidden fees! Everything you need is included
Start for just $179, no insurance required + free shipping

GLP-1 for Just $179

100k Members HSA/FSA Approved From $179

The FDA formally requested that semaspace.com cease offering any unapproved and misbranded drugs for sale to US consumers. The current operating status of semaspace.com and whether the site has complied with the FDA’s warning letter are unknown at the time of writing. Patients should exercise extreme caution and are advised not to purchase from this vendor.

GLP-1 Offerings

At the time of the FDA warning letter, Semaspace sold injectable semaglutide vials in 2mg and 5mg formats, marketed for weight loss. These products were sold without a valid prescription requirement, without FDA approval, and without the pharmacy oversight required for legally compounded medications.

No telehealth infrastructure, licensed prescriber network, or clinical monitoring was associated with the platform. The product was sold as a direct consumer transaction analogous to purchasing from a grey-market research peptide vendor, but with the additional distinction of explicitly marketing the product for human therapeutic use (weight loss and obesity) rather than disclaiming human use.

Pricing — and What Reviewers Say

Specific pricing for Semaspace products at the time of writing is not available through third-party sources. The FDA warning letter preceded the platform’s current operational status. No independent Trustpilot, Google, or consumer health review pool was identified for Semaspace at the time of writing.

The pricing model for vendors in this category is typically significantly below licensed telehealth-compounded GLP-1 programs. The absence of physician oversight, pharmacy accreditation, quality testing, and regulatory compliance all reduces operating costs, which are passed to consumers as lower prices. This cost difference does not represent value; it represents the elimination of the safety infrastructure that legitimate programs provide.

Reviews from Trustpilot and Google

No independent review pool was identified for Semaspace at the time of writing. The absence of consumer reviews on mainstream platforms, combined with the FDA warning letter and the no-prescription sales model, makes independent evaluation of this vendor’s product quality, shipping reliability, or customer service performance impossible through the methods used in this review series.

Compounding Pharmacies Used

Semaspace is not a compounding pharmacy and does not operate through the 503A or 503B compounding pharmacy framework. The semaglutide products sold by Semaspace are unapproved drug products with no disclosed manufacturing source, quality testing, or pharmacy licensure. Patients have no way to verify the origin, purity, concentration, or sterility of products purchased through this vendor.

Note: Semaspace received an FDA warning letter on October 2, 2023, for selling unapproved and misbranded semaglutide drug products, specifically “Generic semaglutide 2mg” and “Generic semaglutide 5mg” injectable vials, sold without a valid prescription requirement and without FDA approval. The FDA explicitly requested the site cease offering these products for sale to US consumers. Semaspace is not a telehealth provider, does not have a licensed prescriber network, and does not operate through licensed compounding pharmacies. Purchasing from this vendor carries significant risks: unknown product purity, absence of clinical oversight, no dosing guidance, no provider support if adverse events occur, and ongoing legal and regulatory uncertainty about the vendor’s compliance status. Patients seeking GLP-1 treatment should use a licensed telehealth provider with a board-certified prescriber and 503A or 503B pharmacy sourcing. Semaspace appears in this review series because it is listed in the weightlossinjections.com directory alongside legitimate providers.